RT Journal Article
SR Electronic
T1 Strong neutralizing antibody responses to SARS-CoV-2 variants following a single vaccine dose in subjects with previous SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.04.22277223
DO 10.1101/2022.07.04.22277223
A1 Ekström, Nina
A1 Haveri, Anu
A1 Solastie, Anna
A1 Virta, Camilla
A1 Österlund, Pamela
A1 Nohynek, Hanna
A1 Nieminen, Tuomo
A1 Ivaska, Lauri
A1 Tähtinen, Paula A.
A1 Lempainen, Johanna
A1 Jalkanen, Pinja
A1 Julkunen, Ilkka
A1 Palmu, Arto A.
A1 Melin, Merit
YR 2022
UL http://medrxiv.org/content/early/2022/07/06/2022.07.04.22277223.abstract
AB Background Previous SARS-CoV-2 infection primes the immune system and thus individuals who recovered from infection have enhanced immune responses to subsequent vaccination (hybrid immunity). However, it remains unclear how well hybrid immunity induced by severe or mild infection can cross-neutralize emerging variants. We aimed to compare the strength and breadth of antibody responses in vaccinated recovered and uninfected subjects.Methods We measured spike-specific IgG and neutralizing antibodies (NAbs) from vaccinated subjects including 320 with hybrid immunity and 20 without previous infection. From 29 subjects with a previous severe or mild infection, we also measured NAb responses against Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2) and Omicron (B.1.1.529/BA.1) variants following vaccination.Results A single vaccine dose induced 2-fold higher anti-spike IgG concentrations and 3-fold higher neutralizing potency of antibodies in previously infected compared to uninfected fully vaccinated subjects. We found similar IgG concentrations in previously infected subjects after one or two vaccine doses. NAb titers were higher in subjects with severe compared to those with mild infection. This difference remained after vaccination with sequentially decreasing titers against Alpha, Beta, Delta, and Omicron variants.Conclusions Hybrid immunity induced strong IgG responses, particularly after severe infection. However, the NAb titers were low against heterologous variants, especially against Omicron.Competing Interest StatementFinnish Institute for Health and Welfare conducts Public-Private Partnership with vaccine manufacturers and has received research funding for studies unrelated to COVID-19 from GlaxoSmithKline Vaccines (N.E, C.V, A.A.P, and M.M as investigators), Pfizer (A.A.P) and Sanofi Pasteur (A.A.P, T.N). The other authors report no potential conflicts of interest.Funding StatementThis study was funded by the Finnish Institute for Health and Welfare and the Academy of Finland (grant numbers 336410, 336431) and Jane and Aatos Erkko Foundation (grant number 5360-cc2fc).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethical committee of the Hospital District of Helsinki and Uusimaa (HUS/1137/2020), the ethical committee of the Southwest Finland health district (ETMK 19/1801/2020) and the Finnish Medicines Agency Fimea as the regulatory authority (European Union drug regulation authority, clinical trials database code 2021-004419-14) gave ethical approval to this study. Written informed consent was obtained from all participants before sample collection.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors